Three out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy, according to results of the screening phase of the phase II STOMP randomized trial.
African-American men were more likely to present with metastases, less likely to receive definitive therapy, and had increased prostate cancer-specific mortality compared with non-African-American men regardless of whether they were privately insured or insured through Medicaid, a study presented at the Genitourinary Cancers Symposium in Orlando, FL found.
Clinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
A simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Mood and adjustment disorders were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with prostate and breast cancer, according to a recent study.